SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%

Aeterna Zentaris Announces Abstract Of Results From First Pediatric Study Of Macimorelin Accepted For Presentation At The 22nd European Congress Of Endocrinology Sep. 5-9

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics

Benzinga · -

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the abstract on study results of its first pediatric study on macimorelin has been selected for presentation at the 22nd European Congress of Endocrinology (e-ECE 2020) being held September 5-9, 2020.
 

The accepted abstract titled Pharmacokinetics and pharmacodynamics of macimorelin acetate (AEZS-130) in paediatric patients with suspected growth hormone deficiency (GHD), will be presented as an ePoster accommodated by an audio commentary during the event.

Abstracts are under embargo until published in Endocrine Abstracts before the start of e-ECE 2020. Endocrine Abstracts is an entirely online, open-access and fully citable collection of all the abstracts from e-ECE 2020. Once the abstract is made public, it will be available on the Company's website.